Study of Nicotinamide Mononucleotide Sustained-release Tablets to Improve Immune Aging and Metabolism in Adults Aged 50 to 70 With Metabolic Conditions

What this Trial Is About

Researchers are evaluating the effects of nicotinamide mononucleotide NMN supplementation on immunosenescence and metabolism in middle-aged and elderly people with metabolic disorders. This randomized, placebo-controlled clinical trial aims to provide new insights into improving immune system aging and potentially preventing glucose and lipid metabolic diseases. The study focuses on adults aged 50 to 70 years who have overweight or obesity and metabolic-related conditions such as fatty liver disease, pre-diabetes, or type 2 diabetes without glucose-lowering therapy. Participants will receive either NMN sustained-release tablets 1000 mg or a matching placebo, taken once daily before breakfast for 26 weeks. Investigator visits will occur at months 1, 3, and 6 during the treatment period. The study includes a placebo group for comparison to assess the effects of NMN on immune cell markers and metabolic health. Throughout the study, participants will undergo evaluations including blood tests, body composition analysis, and cardiorespiratory fitness assessments. The primary measure is the percentage of certain immune cells CD3CD8CD27-CD28- T cells among total CD3CD8 T cells after 26 weeks. Secondary measures include glucose levels, pancreatic beta-cell function, telomere length, and safety labs such as liver and kidney function. Participant safety and treatment effects will be closely monitored during the entire study period.

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.